The Bydureon Phase lll Trial: Supplementary Substudies

The Bydureon Phase lll Trial: Supplementary Substudies
PLEASE DONATE TO HELP US DRIVE THIS RESEARCH FORWARD The Cure Parkinson's Trust (CPT) and the Van Andel Institute (VAI) are delighted to be supporting two sub-studies within the important Bydureon phase lll trial (Exenatide-PD 3) which will begin recruiting from six sites in the UK over the coming months. The rationale for sub-studies is that they provide additional information ... read more
Source: The Cure Parkinson’s TrustPublished on 2020-01-14